958 – Efficacy Of Lisdexamfetamine Dimesylate In Children And Adolescents With Attention-deficit/hyperactivity Disorder: Effect Of Age, Sex And Baseline Disease Severity
Michel Lecendreux(Laboratoire National de Référence), David Coghill(The University of Melbourne), Alessandro Zuddas(University of Cagliari), César A. Soutullo(The University of Texas Health Science Center), Nicholas Higgins(Takeda (United States)), Ralph Bloomfield(AstraZeneca (United Kingdom)), Magnus L. Johnson(University of Houston), Richard Civil(Takeda (United States)), Tobias Banaschewski(Heidelberg University), Colleen Anderson(Takeda (United States)), Liza Squires
Cited by 2
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders
|Cell|2019|1.5k
The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder
|Neuroscience & Biobehavioral Reviews|2021|1.4k
Attention-deficit/hyperactivity disorder
|Nature Reviews Disease Primers|2015|1.3k